Single User License
INR 128440
Site License
INR 256880
Corporate User License
INR 385320

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Gastric Ulcers-Pipeline Review, H1 2017

Gastric Ulcers-Pipeline Review, H1 2017


  • Products Id :- GMDHC9181IDB
  • |
  • Pages: 42
  • |
  • April 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Gastric Ulcers-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Ulcers-Pipeline Review, H1 2017, provides an overview of the Gastric Ulcers (Gastrointestinal) pipeline landscape.

Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, retching, nausea or vomiting and unexplained weight loss. Predisposing factors include smoking and alcoholism. Treatment includes antibiotics and antacids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Ulcers-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gastric Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I and Preclinical stages are 1, 5 and 5 respectively.

Gastric Ulcers (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Ulcers (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Gastric Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Gastric Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Gastric Ulcers (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Ulcers (Gastrointestinal)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Gastric Ulcers (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Gastric Ulcers (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Gastric Ulcers-Overview

Gastric Ulcers-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Gastric Ulcers-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gastric Ulcers-Companies Involved in Therapeutics Development

Astellas Pharma Inc

Boryung Pharmaceutical Co Ltd

ChoDang Pharm Co Ltd

Daewoong Pharmaceutical Co Ltd

Kukje Pharmaceutical Industry Co Ltd

RaQualia Pharma Inc

XuanZhu Pharma Co Ltd

Gastric Ulcers-Drug Profiles

(lafutidine + irsogladine maleate)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anaprazole sodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-6537-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGC-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cholesteryl glucoside-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWJ-1386-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWJ-206-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWP-14012-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KJ-14001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Gastric Ulcers-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tegoprazan-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gastric Ulcers-Dormant Projects

Gastric Ulcers-Discontinued Products

Gastric Ulcers-Product Development Milestones

Featured News & Press Releases

Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies

Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck

Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations

Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy

Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.

Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)

Jun 01, 2007: AstraZeneca's Prilosec Patents Upheld By Court

Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court

Aug 08, 2003: Astrazeneca to Seek Triple Damages in Patent Infringement Lawsuit Against Mylan Pharmaceuticals

Oct 23, 2001: Prilosec US litigation

May 02, 2001: Astrazeneca Receives Six Months' Market Exclusivity for Prilosec

May 02, 2001: Court Denies Generic's Application for Summary Judgement on Prilosec Patent

Apr 23, 2001: Astrazeneca Files Lawsuit Against Apotex Corporation and Torpharm for Patent Infringement

Dec 19, 2000: Astrazeneca Wins Losec Patent Litigation in Canada

Oct 20, 2000: Joint FDA Advisory Committee Confirms OTC Prilosec (Omeprazole) Safety and Efficacy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Gastric Ulcers, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Gastric Ulcers, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Gastric Ulcers-Pipeline by Astellas Pharma Inc, H1 2017

Gastric Ulcers-Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017

Gastric Ulcers-Pipeline by ChoDang Pharm Co Ltd, H1 2017

Gastric Ulcers-Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017

Gastric Ulcers-Pipeline by Kukje Pharmaceutical Industry Co Ltd, H1 2017

Gastric Ulcers-Pipeline by RaQualia Pharma Inc, H1 2017

Gastric Ulcers-Pipeline by XuanZhu Pharma Co Ltd, H1 2017

Gastric Ulcers-Dormant Projects, H1 2017

Gastric Ulcers-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Astellas Pharma Inc, Boryung Pharmaceutical Co Ltd, ChoDang Pharm Co Ltd, Daewoong Pharmaceutical Co Ltd, Kukje Pharmaceutical Industry Co Ltd, RaQualia Pharma Inc, XuanZhu Pharma Co Ltd


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com